List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 814 studies with search of:   "Bevacizumab"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
Condition: Diabetic Retinopathy
Interventions: Procedure: Laser Photocoagulation;   Drug: Bevacizumab;   Drug: Bevacizumab;   Drug: Bevacizumab;   Drug: Bevacizumab
2 Recruiting Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Vinorelbine;   Drug: Cisplatin;   Drug: Bevacizumab;   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Bevacizumab;   Drug: Docetaxel;   Drug: Cisplatin;   Drug: Bevacizumab
3 Completed Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
Condition: Macular Degeneration
Interventions: Drug: Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (SHAM) and bevacizumab
4 Active, not recruiting Combination Therapy for Age-Related Macular Degeneration.
Condition: Age Related Macular Degeneration
Interventions: Drug: Avastin (Bevacizumab);   Drug: Bevacizumab;   Drug: Bevacizumab;   Drug: Bevacizumab
5 Recruiting Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC
Condition: Colorectal Cancer
Interventions: Drug: Irinotecan;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: Capecitabine;   Drug: Bevacizumab;   Drug: Bevacizumab;   Drug: Irinotecan
6 Recruiting Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema
Condition: Diabetic Macular Edema
Interventions: Drug: Bevacizumab intravitreal;   Drug: Triamcinolone;   Drug: Triamcinolone + Bevacizumab
7 Active, not recruiting Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
Conditions: Age Related Macular Degeneration;   Choroidal Neovascularization;   Macular Edema
Interventions: Drug: Bevacizumab and verteporfin photodynamic therapy;   Drug: Bevacizumab and visudyne photodynamic therapy
8 Active, not recruiting A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone + Bevacizumab;   Drug: Ixabepilone + Bevacizumab;   Drug: Paclitaxel + Bevacizumab
9 Not yet recruiting RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-Line Treatment of GBM
Condition: Glioblastoma Multiforme
Interventions: Radiation: Radiation therapy;   Drug: Temozolomide;   Drug: Bevacizumab;   Drug: Bevacizumab;   Drug: Everolimus
10 Terminated Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Cetuximab + Bevacizumab;   Drug: Cetuximab + Bevacizumab + Gemcitabine
11 Recruiting Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
Conditions: Advanced Ovarian Carcinoma;   Primary Peritoneal Carcinoma;   Ovarian Carcinosarcoma
Intervention: Drug: Avastin
12 Recruiting A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-Agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Condition: Breast Cancer
Interventions: Drug: Bevacizumab (Avastin);   Drug: Bevacizumab (Avastin);   Drug: Bevacizumab (avastin);   Drug: Bevacizumab (avastin);   Drug: Bevacizumab (avastin);   Drug: Bevacizumab (avastin)
13 Recruiting Pre-Operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
Conditions: Esophageal Cancer;   Gastric Cancer
Intervention: Drug: epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
14 Recruiting Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Conditions: Renal Cell Carcinoma;   Kidney Cancer;   Urogenital Cancer
Interventions: Drug: Bevacizumab (Avastin®) + Temsirolimus (Torisel®);   Drug: Bevacizumab (Avastin®) + Interferon-Alfa (Roferon®)
15 Recruiting Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
Conditions: Hepatocellular Carcinoma;   Liver Cancer
Interventions: Drug: Bevacizumab (Avastin);   Drug: Erlotinib
16 Recruiting A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
Conditions: Non-Small Cell Lung Cancer;   Malignant Pleural Effusions
Interventions: Drug: Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6);   Drug: Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)
17 Recruiting Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-Small Cell Cell Lung Cancer
Condition: Toxicity
Intervention: Biological: bevacizumab
18 Recruiting Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Bevacizumab and Etoposide
19 Recruiting Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With MPM
Condition: Mesothelioma
Intervention: Drug: Carboplatin, Bevacizumab and Pemetrexed
20 Completed Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization
Conditions: Lipid Keratopathy;   Penetrating Keratoplasty;   Herpetic Keratopathy;   Rosacea
Intervention: Drug: subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)

Previous Page Studies Shown (1-20) Next (21-40)
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services